Prostate cancer, Castration-resistant prostate cancer, Prostate cancer with bone metastasis
Conditions
Interventions
Metastatic prostate cancer:None
Localized high-risk prostate cancer:None
Low-risk prostate cancer:None
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed prostate adenocarcinoma, with pathological type and grade meeting the WHO prostate cancer classification and ISUP/Gleason scoring criteria; 2. Tumor tissue obtained by surgery or biopsy is available for immunohistochemistry, molecular, or metabolomic testing, and the sample quality meets testing requirements; 3. Complete clinical data are available, including imaging examinations (such as MRI, CT, and bone scan), serum PSA levels, pathology reports, and treatment information; 4. Age >= 18 years, male; 5. Good general condition (ECOG performance status 0–2) and able to tolerate tissue collection and related experimental procedures; 6. No other active malignancies or severe systemic diseases, and able to comply with study requirements; 7. Able to understand and voluntarily sign the informed consent form, and willing to provide specimens and relevant clinical information for this study.
Exclusion criteria
Exclusion criteria: 1. Pathological diagnosis is inconclusive, or the tissue sample is insufficient to meet subsequent testing requirements; 2. Previously received systemic antitumor therapy (including chemotherapy, radiotherapy, endocrine therapy, or targeted therapy) without available tumor tissue specimens; 3. Presence of severe cardiovascular, hepatic, renal, or respiratory diseases, rendering the patient unable to tolerate sample collection or laboratory testing; 4. Presence of severe infection, autoimmune disease, or metabolic disorder that may affect the analysis of metabolic pathways; 5. Presence of severe mental disorders, cognitive impairment, or other conditions affecting compliance; 6. Participation in other interventional clinical trials that may interfere with the results of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;multi-omics features; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological grading;Biochemical recurrence; | — |
Countries
China
Contacts
Public ContactQi Zhang
Zhejiang Provincial People's Hospital
Outcome results
None listed